Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2006

View Archived Issues

Axcan Pharma reports Q4 highlights

BioAlliance cleared for phase II/III trial of doxorubicin Transdrug

Ariad presents novel oral Bcr-Abl kinase inhibitor with broad activity

Novel HDAC inhibitor shows superiority to vorinostat in vitro

Promising therapeutics for multiple myeloma presented at the ASH meeting

Snapshots of newly reported clinical trials in lymphoma

Progress in clinical developments for Loramyc and acyclovir Lauriad

Nanobody collaboration achieves first milestone

Review confirms rEV-131 findings in allergic rhinitis

Preclinical findings for carrier molecule BP-Cx-1

Pivotal studies for NM-100060 in onychomycosis begin screening

Nippon Shinyaku and Roche terminate NS-220 license agreement

FDA Joint Advisory Committee makes recommendations regarding Ketek

Advisory Committee recommends alternative phase II study for Hemopure

Pharmexa and Ichor collaborate on HER-2 DNA AutoVac

European Commission clearance for Merck KGaA's acquisition of Serono

Abbott completes acquisition of Kos

Lilly amends offer for Icos

Alliance gets French go-ahead for phase II trial of Oxygent

Enrollment completed in phase IIb study of elocalcitol in BPH

Ambrisentan NDA filed in pulmonary arterial hypertension

Astellas resubmits NDA for vernakalant hydrochloride

Orphan Therapeutics plans rolling NDA for Lucassin

Novel possible psychopharmacologic drugs identified in recent patents

Tracleer shows efficacy in mildly symptomatic PAH patients

New preclinical data on anticonvulsants

Proellex achieves statistically significant pain reduction in endometriosis

Sankyo patents novel antiplatelet agents

Novel analgesic agents imparted in recent Vertex and Gruenenthal patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...